	US 12,274,747 B2
	Compositions and methods for treating cytokine release syndrome
Kara Olson, White Plains, NY (US); Olga Sineshchekova, Pleasantville, NY (US); Eric Smith, New York, NY (US); and Chia-Yang Lin, Scarsdale, NY (US)
Assigned to Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed by Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed on Jan. 28, 2022, as Appl. No. 17/587,501.
Claims priority of provisional application 63/142,643, filed on Jan. 28, 2021.
Prior Publication US 2022/0233690 A1, Jul. 28, 2022
Int. Cl. A61K 39/395 (2006.01); A61K 35/17 (2015.01); A61K 38/17 (2006.01); A61P 35/00 (2006.01); A61P 37/06 (2006.01)

CPC A61K 39/3955 (2013.01) [A61K 35/17 (2013.01); A61K 38/1774 (2013.01); A61K 39/39558 (2013.01); A61P 35/00 (2018.01); A61P 37/06 (2018.01)]

33 Claims

1. A method of treating cancer and inhibiting cytokine release syndrome in a subject, comprising conjointly administering to the subject:

(a) a multi-specific antigen binding molecule comprising a first antigen-binding domain that specifically binds to CD3 and a second antigen-binding domain that specifically binds to a tumor antigen; and

(b) a CD40 antagonist or a CAR-T cell expressing a CD40 antagonist, wherein the CD40 antagonist is an antibody or antigen-binding fragment thereof.